艾迪冻干粉抗肿瘤作用的实验研究  

An Experimental Study of the Antineoplastic Activity of AIDI Lyophilized Powder

作　　者：王涛[1] 孙世伟[1] 林佳亮[1] 崔颖[1] 曾凡波[1] 

机构地区：[1]华中科技大学同济医学院药学院药物研究实验室,武汉430030

出　　处：《医药导报》2005年第6期464-467,共4页Herald of Medicine

摘　　要：目的研究艾迪冻干粉的抗癌活性,为临床应用提供实验依据。方法应用小鼠S180、H22肿瘤体内抗肿瘤试验和体外MTT法检测艾迪冻干粉对S180、H22、HepG2等3种不同来源肿瘤细胞的生长抑制作用;采用Hoechst33342/PI双染法检测药物对人肝癌细胞株HepG2诱导凋亡的作用。结果艾迪冻干粉可以通过直接的细胞毒作用和诱导细胞凋亡对小鼠肿瘤细胞S180、H22和人肝癌细胞HepG2起到生长抑制作用;MTT法研究结果表明,该药物对S180、H22、HepG2细胞的半数抑制浓度(IC50)分别为(0.521±0.272),(0.801±0.333),(0.588±0.376)mg·mL1。结论艾迪冻干粉具有抗肿瘤作用,可能成为临床治疗癌症的有效药物。Objective To study the antineoplastic activity of the AIDI lyophilized powder so as to provide experimental basis for its clinical application. Methods The in vivo antineoplastic activity of the AIDI lyophilized powder was assayed in mice bearing S 180 and H 22 tumors while MTT test was used for the examination of the in vitro antineoplastic activity of the powder on S 180 and H 22 tumor cells.The apoptosis inducing effect of the powder on human liver cancer cells HepG 2 was detected with the Hoechst 33342/PI doubled fluorescent staining. Results The AIDI lyophilized powder was shown to exert growth-inhibiting effect on murine tumor cells S 180 and H 22 as well as human liver cancer cells HepG 2 either by direct cytotoxicity or induction of apoptosis. The results of the MTT test showed that the median inhibition concentrations(IC 50) of the powder for mouse tumor cells S 180,H 22 and human liver cancer cells HepG 2, were(0.521±0.272)mg·mL -1, (0.801±0.333) mg·mL -1 and (0.588± 0.376) mg·mL -1, respectively. Conclusion The AIDI lyophilized powder was shown to have antineoplastic activity and may therefore be an effective drug for the treatment of cancer in the clinic.

关 键 词：艾迪冻干粉 抗肿瘤 细胞凋亡 

分 类 号：R979.1[医药卫生—药品] R286[医药卫生—药学]